Leerink Partnrs Decreases Earnings Estimates for Belite Bio

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Equities research analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for Belite Bio in a report released on Sunday, November 23rd. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($2.10) per share for the year, down from their prior estimate of ($2.05). The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. Leerink Partnrs also issued estimates for Belite Bio’s Q4 2025 earnings at ($0.50) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at ($1.00) EPS, FY2028 earnings at $3.40 EPS and FY2029 earnings at $11.30 EPS.

Several other research firms also recently issued reports on BLTE. Mizuho started coverage on Belite Bio in a research note on Thursday, November 20th. They set a “neutral” rating and a $105.00 price target for the company. Wall Street Zen lowered shares of Belite Bio from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. HC Wainwright reduced their price objective on shares of Belite Bio from $100.00 to $98.00 and set a “buy” rating for the company in a research note on Monday, September 15th. Zacks Research upgraded shares of Belite Bio from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 16th. Finally, Cantor Fitzgerald initiated coverage on shares of Belite Bio in a report on Monday. They issued an “overweight” rating and a $154.00 target price on the stock. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $122.25.

Belite Bio Trading Up 1.4%

Shares of NASDAQ:BLTE opened at $129.62 on Wednesday. The stock has a market capitalization of $4.52 billion, a PE ratio of -67.51 and a beta of -1.42. Belite Bio has a 1 year low of $49.00 and a 1 year high of $144.99. The firm has a fifty day moving average price of $95.67 and a 200 day moving average price of $74.83.

Belite Bio (NASDAQ:BLTE) last posted its earnings results on Monday, November 10th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.12).

Hedge Funds Weigh In On Belite Bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. bought a new stake in Belite Bio in the 3rd quarter valued at $64,750,000. Vestal Point Capital LP acquired a new position in shares of Belite Bio during the third quarter valued at about $23,125,000. Marshall Wace LLP lifted its stake in shares of Belite Bio by 1,876.6% in the third quarter. Marshall Wace LLP now owns 187,500 shares of the company’s stock valued at $13,875,000 after buying an additional 178,014 shares during the period. Alyeska Investment Group L.P. bought a new stake in shares of Belite Bio in the first quarter valued at about $5,538,000. Finally, Millennium Management LLC acquired a new stake in Belite Bio during the third quarter worth about $1,535,000. Institutional investors own 0.53% of the company’s stock.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.